Literature DB >> 9238614

Hyperhomocysteinaemia and end stage renal disease.

A Gupta1, K Robinson.   

Abstract

Vascular disease is a major cause of morbidity and mortality in end stage renal failure patients and cannot be explained entirely by the prevalence of traditional risk factors for atherosclerosis. A high plasma homocysteine concentration, which is a risk factor for vascular disease is found in patients with end stage renal disease. The exact cause for the hyperhomocysteinaemia seen in these patients is unknown, but is probably related to altered renal metabolism of homocysteine. High homocysteine concentrations may also be attributable to a deficiency of folate, vitamin B6 or vitamin B12 although, because of supplementation, these vitamins may be present in high concentrations in renal patients. The occurrence of hyperhomocysteinaemia despite high plasma vitamin concentration could be due to altered metabolism or inhibition of intracellular vitamin activity. A number of studies have now established hyperhomocystinaemia to be an independent risk factor for atherosclerosis in patients with end-stage renal disease. Plasma homocysteine concentrations can be reduced by administration of folic acid either alone or combined with vitamin B12 or vitamin B6. The effects of such reduction on vascular risk in renal failure patients needs further study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9238614

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  5 in total

Review 1.  Mechanisms of homocysteine-induced glomerular injury and sclerosis.

Authors:  Fan Yi; Pin-Lan Li
Journal:  Am J Nephrol       Date:  2007-11-07       Impact factor: 3.754

2.  Homocysteine and left ventricular hypertrophy in children with chronic renal failure.

Authors:  Hakan M Poyrazoğlu; Ruhan Düşünsel; Figen Narin; Zübeyde Gündüz; Nazmi Narin; Musa Karakükçü; Fulya Tahan
Journal:  Pediatr Nephrol       Date:  2003-12-05       Impact factor: 3.714

3.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.

Authors:  J Jankowski; M van der Giet; V Jankowski; S Schmidt; M Hemeier; B Mahn; G Giebing; M Tolle; H Luftmann; H Schluter; W Zidek; M Tepel
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  Hyperhomocysteinemia increases the risk of chronic kidney disease in a Chinese middle-aged and elderly population-based cohort.

Authors:  Xianglei Kong; Xiaojing Ma; Chengyin Zhang; Hong Su; Dongmei Xu
Journal:  Int Urol Nephrol       Date:  2016-11-07       Impact factor: 2.370

Review 5.  Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update.

Authors:  Cheng Wan; Hua Su; Chun Zhang
Journal:  Oxid Med Cell Longev       Date:  2016-08-15       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.